Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
Published version of a preprint
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Purpose: Several MCL-1 inhibitors (MCL-1i), including AMG-176 and AZD5991, have shown promise in preclinical studies and are being tested for the treatment of hematologic malignancies. A unique feature of these agents is induction and stability of Mcl-1 protein; however, the precise mechanism is unknown. We aim to study the mechanism of MCL-1i–induced Mcl-1 protein stability. Experimental Design: Using several B-cell leukemia and lymphoma cell lines and primary chronic lymphocytic leukemia (CLL) lymphocytes, we evaluated molecular events associated with Mcl-1 protein stability including protein half-life, reverse-phase protein array, protein–protein interaction, phosphorylation, ubiquitination, and de-ubiquitination, followed by molecular simulation and modeling. Results: Using both in vivo and in vitro analysis, we demonstrate that MCL-1i–induced Mcl-1 protein stability is predominantly associated with defective Mcl-1 ubiquitination and concurrent apoptosis induction in both cell lines and primary CLL subjects. These MCL1i also induced ERK-mediated Mcl-1Thr163 phosphorylation, which partially contributed to Mcl-1 stability. Disruption of Mcl-1:Noxa interaction followed by Noxa degradation, enhanced Mcl-1 de-ubiquitination by USP9x, and Mule destabilization are the major effects of these inhibitors. However, unlike other BH3 proteins, Mule:Mcl-1 interaction was unaffected by MCL-1i. WP1130, a global deubiquitinase (DUB) inhibitor, abrogated Mcl-1 induction reaffirming a critical role of DUBs in the observed Mcl-1 protein stability. Further, in vitro ubiquitination studies of Mcl-1 showed distinct difference among these inhibitors. Conclusions: We conclude that MCL-1i blocked Mcl-1 ubiquitination via enhanced de-ubiquitination and dissociation of Mcl-1 from Noxa, Bak and Bax, and Mule de-stabilization. These are critical events associated with increased Mcl-1 protein stability with AMG-176 and AZD5991.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and recently MCL-1 antagonists have been shown to potentiate MCL-1 accumulation in chronic lymphocytic leukemia (CLL) cells by diminishing MCL-1 ubiquitination and degradation.30”
From Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia (2025) · cites this paper as [30]
In the citing paper
“Several studies have demonstrated that B-cell lymphoma 2 (Bcl-2) Homology 3 (BH3)-mimetics induce MCL-1 up-regulation as a compensatory response in leukemia cells.”
From Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia (2025) · cites this paper as [30]
In the citing paper
“However, their effectiveness in acute myeloid leukemia (AML) is limited by compensatory MCL-1 accumulation via the ubiquitin proteasome system.”
From Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia (2025) · cites this paper as [30]
In the citing paper
“However, a recent study by Tantawy et al., showed that in CLL cells, MCL-1 antagonists disrupted MCL-1-related ubiquitin ligases, thus disabling MCL-1 degradation and promoting its accumulation.30”
From Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia (2025) · cites this paper as [30]
In the citing paper
“As reported in CLL cells,30 S63845 sharply increased MCL-1 expression in AML cells. However, SKI-606 co-administration blocked this event (Fig. 2a, upper panel).”
From Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia (2025) · cites this paper as [30]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature · doi:10.1038/nature19830 · Cited by 1,047
Maurer, U., Charvet, C., Wagman, A. S., Dejardin, E., & Green, D. R. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.02.009 · Cited by 881
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival
Schwickart, M., Huang, X., Lill, J. R., Liu, J., Ferrando, R., French, D. M., Maecker, H., O’Rourke, K., Bazan, F., Eastham-Anderson, J., et al. (2010) · Nature · doi:10.1038/nature08646 · Cited by 628
Leverson, J. D., Zhang, H., Chen, J., Tahir, S. K., Phillips, D. C., Xue, J., Nimmer, P., Jin, S., Smith, M., Xiao, Y., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.561 · Cited by 440
Caenepeel, S., Brown, S. P., Belmontes, B., Moody, G., Keegan, K. S., Chui, D., Whittington, D. A., Huang, X., Poppe, L., Cheng, A. C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0387 · Cited by 432
Domina, A. M., Vrana, J. A., Gregory, M. A., Hann, S. R., & Craig, R. W. (2004) · Oncogene · doi:10.1038/sj.onc.1207692 · Cited by 327
mTORC1 promotes survival through translational control of Mcl-1
Mills, J. R., Hippo, Y., Robert, F., Chen, S. M. H., Malina, A., Lin, C.-J., Trojahn, U., Wendel, H.-G., Charest, A., Bronson, R. T., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804821105 · Cited by 285
Research works printed but not linked: 39
- Davids, 2012, Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia, Blood, 120, 3501, 10.1182/blood-2012-02-414060 · DOI
- Krajewski, 1995, Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo, Am J Pathol, 146, 1309
- Campbell, 2018, MCL-1 is a prognostic indicator and drug target in breast cancer, Cell Death Dis, 9, 1, 10.1038/s41419-017-0035-2 · DOI · Paper page
- Beroukhim, 2010, The landscape of somatic copy-number alteration across human cancers, Nature, 463, 899, 10.1038/nature08822 · DOI · Paper page
- Tron, 2018, Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia, Nat Commun, 9, 1, 10.1038/s41467-018-07551-w · DOI · Paper page
- Koch, 2019, Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas, Blood, 133, 566, 10.1182/blood-2018-07-865527 · DOI · Paper page
- Li, 2019, The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells, Leukemia, 33, 262, 10.1038/s41375-018-0201-2 · DOI
- Yi, 2020, AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia, Clin Cancer Res, 26, 3856, 10.1158/1078-0432.CCR-19-1397 · DOI · Paper page
- Yang, 1996, MCL-1, a member of the BCL-2 family, is induced rapidly in response to signals for cell differentiation or death, but not to signals for cell proliferation, J Cell Physiol, 166, 523, 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R · DOI · Paper page
- Jourdan, 2000, Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1, Cell Death & Differentiation, 7, 1244, 10.1038/sj.cdd.4400758 · DOI
- Fritsch, 2007, Translational repression of MCL-1 couples stress-induced eIF2α phosphorylation to mitochondrial apoptosis initiation, J Biol Chem, 282, 22551, 10.1074/jbc.M702673200 · DOI · Paper page
- Mojsa, 2014, Mcl-1 ubiquitination: unique regulation of an essential survival protein, Cells, 3, 418, 10.3390/cells3020418 · DOI · Paper page
- Zhong, 2005, Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis, Cell, 121, 1085, 10.1016/j.cell.2005.06.009 · DOI · Paper page
- Magiera, 2013, Trim17-mediated ubiquitination and degradation of Mcl-1 initiate apoptosis in neurons, Cell Death & Differentiation, 20, 281, 10.1038/cdd.2012.124 · DOI
- Ding, 2007, Degradation of Mcl-1 by β-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization, Mol Cell Biol, 27, 4006, 10.1128/MCB.00620-06 · DOI · Paper page
- Wang, 2014, Role of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis, Cell Death & Differentiation, 21, 1160, 10.1038/cdd.2014.42 · DOI
- Zhang, 2018, Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors, Nat Commun, 9, 1
- Sarkar, 2020, Ataxia telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma, Haematologica, 106, 495, 10.3324/haematol.2019.234385 · DOI
- Neutzner, 2012, The ubiquitin/proteasome system-dependent control of mitochondrial steps in apoptosis, Semin Cell Dev Biol, 23, 499, 10.1016/j.semcdb.2012.03.019 · DOI
- Tong, 2017, Mcl-1 degradation is required for targeted therapeutics to eradicate colon cancer cells, Cancer Res, 77, 2512, 10.1158/0008-5472.CAN-16-3242 · DOI · Paper page
- Nakajima, 2014, Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer, Cell Death Dis, 5, e1052, 10.1038/cddis.2014.6 · DOI
- Kapuria, 2010, Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis, Cancer Res, 70, 9265, 10.1158/0008-5472.CAN-10-1530 · DOI · Paper page
- Peterson, 2015, Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies, Blood, 125, 3588, 10.1182/blood-2014-10-605584 · DOI · Paper page
- Warr, 2005, BH3-ligand regulates access of MCL-1 to its E3 ligase, FEBS Lett, 579, 5603, 10.1016/j.febslet.2005.09.028 · DOI · Paper page
- Gomez-Bougie, 2011, Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1/USP9X interaction, Biochem Biophys Res Commun, 413, 460, 10.1016/j.bbrc.2011.08.118 · DOI
- Warr, 2011, Mitochondrion-dependent N-terminal processing of outer membrane Mcl-1 protein removes an essential Mule/Lasu1 protein-binding site, J Biol Chem, 286, 25098, 10.1074/jbc.M111.218321 · DOI
- Doi, 2012, Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation, J Biol Chem, 287, 10224, 10.1074/jbc.M111.334532 · DOI · Paper page
- Song, 2016, Deactivation of Mcl-1 by dual-function small-molecule inhibitors targeting the Bcl-2 homology 3 domain and facilitating Mcl-1 ubiquitination, Angew Chem Int Ed, 55, 14250, 10.1002/anie.201606543 · DOI · Paper page
- Hird, 2019, Recent advances in the development of Mcl-1 inhibitors for cancer therapy, Pharmacol Ther, 198, 59, 10.1016/j.pharmthera.2019.02.007 · DOI · Paper page
- Miles, 2021, Selective affimers recognise the BCL-2 family proteins BCL-xL and MCL-1 through noncanonical structural motifs, ChemBioChem, 22, 232, 10.1002/cbic.202000585 · DOI
- Harris, 2012, Genetic disruption of USP9X sensitizes colorectal cancer cells to 5-fluorouracil, Cancer Biol Ther, 13, 1319, 10.4161/cbt.21792 · DOI
- D'arcy, 2011, Inhibition of proteasome deubiquitinating activity as a new cancer therapy, Nat Med, 17, 1636, 10.1038/nm.2536 · DOI · Paper page
- Bianchetti, 2018, Usp9X regulates cell death in malignant peripheral nerve sheath tumors, Sci Rep, 8, 1, 10.1038/s41598-018-35806-5 · DOI
- Rasmussen, 2020, MCL-1 inhibition by selective BH3 mimetics disrupts mitochondrial dynamics causing loss of viability and functionality of human cardiomyocytes, IScience, 23, 101015, 10.1016/j.isci.2020.101015 · DOI · Paper page
- Dadson, 2017, The E3 ligase Mule protects the heart against oxidative stress and mitochondrial dysfunction through Myc-dependent inactivation of Pgc-1α and Pink1, Sci Rep, 7, 1, 10.1038/srep41490 · DOI
- Gu, 2016, Rapamycin inhibits cardiac hypertrophy by promoting autophagy via the MEK/ERK/Beclin-1 pathway, Front Physiol, 7, 104, 10.3389/fphys.2016.00104 · DOI
- Yitzhaki, 2009, Autophagy is required for preconditioning by the adenosine A1 receptor-selective agonist CCPA, Basic Res Cardiol, 104, 157, 10.1007/s00395-009-0006-6 · DOI · Paper page
- Boengler, 2009, Loss of cardioprotection with ageing, Cardiovasc Res, 83, 247, 10.1093/cvr/cvp033 · DOI · Paper page
- Xu, 2019, Oridonin protects against cardiac hypertrophy by promoting P21-related autophagy, Cell Death Dis, 10, 1, 10.1038/s41419-019-1617-y · DOI
Cited by
Targeting MCL-1 protein to treat cancer: opportunities and challenges
Tantawy, S. I., Timofeeva, N., Sarkar, A., & Gandhi, V. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1226289 · Cited by 90
Self-citationSrc inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia
Hu, X., Li, L., Nkwocha, J., Kmieciak, M., Shang, S., Cowart, L. A., Yue, Y., Horimoto, K., Hawkridge, A., Rijal, A., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02125-x · Cited by 15
Metadata
- Authors
- Tantawy, S. I., Sarkar, A., Hubner, S., Tan, Z., Wierda, W. G., Eldeib, A., Zhang, S., Kornblau, S., & Gandhi, V.
- Affiliations
- 1Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 4Center for Drug Discovery, Department of Pathology and Immunology, Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, Texas.
- 2Department of Internal Medicine, College of Medicine, Suez Canal University, Ismailia, Egypt.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2022-11-08
- Volume
- 29
- Issue
- 2
- Pages
- 446-457
- ISSN
- 1078-0432
- 1557-3265
- Cited by
- 34
- References
- 7
- Language
- en
- Funders
- CLL Global Research Foundation (Alliance Grant)
- University of Texas MD Anderson Cancer Center (CLL Moon Shot)
- Cancer Prevention and Research Institute of Texas (RR220039)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-22-2088
- The paper
- Tantawy, S. I., Sarkar, A., Hubner, S., Tan, Z., Wierda, W. G., Eldeib, A., Zhang, S., Kornblau, S., & Gandhi, V. (2023). Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-22-2088
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.